Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
A panel of two halves for multiple myeloma Car-Ts
Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.
Multiple myeloma Car-Ts face a US grilling
The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.
Carvykti joins Abecma in adcom limbo
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
